Literature DB >> 7587742

Reproducibility in DNA flow cytometric analysis of breast cancer: comparison of 12 laboratories' results for 67 sample homogenates.

B Baldetorp1, P O Bendahl, M Fernö, K Alanen, U Delle, U Falkmer, B Hansson-Aggesjö, T Höckenström, A Lindgren, L Mossberg.   

Abstract

Flow cytometric (FCM) DNA analysis yields information on ploidy status and the S-phase fraction (SPF), variables of prognostic importance in breast cancer. The clinical value of the SPF is currently being evaluated in prospective randomized trials. The widespread use of FCM DNA analysis emphasizes the importance of reproducibility (both intra- and interlaboratory). In this study, 67 nuclear suspensions of breast cancer samples were analyzed by 12 laboratories routinely performing FCM DNA analysis in breast cancer. No general guidelines were imposed; each laboratory used its own standard protocols. For DNA ploidy status (diploid vs. non-diploid), agreement was complete for 79% (53/67) of the samples, compared with 64% (43/67) of samples when tetraploidy was considered [i.e., euploid (diploid+tetraploid) vs. aneuploid (the remaining non-diploid)]. For the SPF, pairwise comparison of the results of all 12 laboratories yielded a mean Spearman's rank correlation of 0.78 (range: 0.54-0.93). For those 39 samples being categorized in low or high SPF by all laboratories, all agreed in 14 samples (36%). Similar patterns were obtained with kappa measures, agreement being good for ploidy status (diploid vs. non-diploid; overall kappa = 0.87 and 0.74 for euploid vs. aneuploid), but moderate for the SPF [overall kappa = 0.47 (for low SPF vs. high SPF vs. "no SPF reported")]. Discrepancies were chiefly attributable to differences in the categorization of the S-phase values, rather than in FCM procedures, other critical differences being in the detection and interpretation of near-diploid and small non-diploid cell populations, the definition of tetraploidy, and the choice and execution of the method used for S-phase estimation. Based on the observations of this study, detailed guidelines for FCM analysis and interpretation of data are proposed in the Appendix. Some issues remain, however, e.g., to standardize a method for S-phase calculation and tetraploid definition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587742     DOI: 10.1002/cyto.990220207

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  9 in total

1.  Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.

Authors:  A E Pinto; S André; J Soares
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.

Authors:  A E Pinto; S André; T Pereira; S Nóbrega; J Soares
Journal:  J Clin Pathol       Date:  2001-07       Impact factor: 3.411

3.  Prognostic relevance of DNA flow cytometry in breast cancer revisited: The 25-year experience of the Portuguese Institute of Oncology of Lisbon.

Authors:  António E Pinto; Teresa Pereira; Giovani L Silva; Saudade André
Journal:  Oncol Lett       Date:  2017-02-13       Impact factor: 2.967

Review 4.  Biomolecular features of clinical relevance in breast cancer.

Authors:  Maria Grazia Daidone; Angelo Paradiso; Massimo Gion; Nadia Harbeck; Fred Sweep; Manfred Schmitt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-17       Impact factor: 9.236

5.  CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.

Authors:  Eleonor Olsson; Gabriella Honeth; Pär-Ola Bendahl; Lao H Saal; Sofia Gruvberger-Saal; Markus Ringnér; Johan Vallon-Christersson; Göran Jönsson; Karolina Holm; Kristina Lövgren; Mårten Fernö; Dorthe Grabau; Ake Borg; Cecilia Hegardt
Journal:  BMC Cancer       Date:  2011-09-29       Impact factor: 4.430

6.  Prognostic implications of various models for calculation of S-phase fraction in 259 patients with soft tissue sarcoma.

Authors:  P Gustafson; B Baldetorp; M Fernö; M Akerman
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

7.  Quantification of cell cycle kinetics by EdU (5-ethynyl-2'-deoxyuridine)-coupled-fluorescence-intensity analysis.

Authors:  Pedro D Pereira; Ana Serra-Caetano; Marisa Cabrita; Evguenia Bekman; José Braga; José Rino; Renè Santus; Paulo L Filipe; Ana E Sousa; João A Ferreira
Journal:  Oncotarget       Date:  2017-06-20

8.  The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Authors:  Gabriella Honeth; Pär-Ola Bendahl; Markus Ringnér; Lao H Saal; Sofia K Gruvberger-Saal; Kristina Lövgren; Dorthe Grabau; Mårten Fernö; Ake Borg; Cecilia Hegardt
Journal:  Breast Cancer Res       Date:  2008-06-17       Impact factor: 6.466

9.  Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.

Authors:  Jiangang Liu; Andrew Campen; Shuguang Huang; Sheng-Bin Peng; Xiang Ye; Mathew Palakal; A Keith Dunker; Yuni Xia; Shuyu Li
Journal:  BMC Med Genomics       Date:  2008-09-11       Impact factor: 3.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.